Hycamtin(topotecan)
Hycamtin, Potactasol, Topotecan (topotecan) is a small molecule pharmaceutical. Topotecan was first approved as Hycamtin on 1996-05-28. It is used to treat non-small-cell lung carcinoma, ovarian neoplasms, small cell carcinoma, small cell lung carcinoma, and uterine cervical neoplasms in the USA. It has been approved in Europe to treat neoplasms, ovarian neoplasms, small cell lung carcinoma, and uterine cervical neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Hycamtin, Topotecan (discontinued: Topotecan)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| hycamtin | New Drug Application | 2023-09-18 |
| topotecan | ANDA | 2024-02-15 |
| topotecan hydrochloride | ANDA | 2024-10-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| ovarian neoplasms | EFO_0003893 | D010051 | C56 |
| non-small-cell lung carcinoma | — | D002289 | — |
| small cell carcinoma | — | D018288 | — |
| uterine cervical neoplasms | — | D002583 | — |
| small cell lung carcinoma | — | D055752 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
459 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | 1 | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | — | — | 1 | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | 1 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Medulloblastoma | D008527 | — | — | — | 1 | — | — | — | 1 |
| Rhabdoid tumor | D018335 | — | — | — | 1 | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | — | 1 | — | — | — | 1 |
| Rhabdomyosarcoma | D012208 | — | — | — | 1 | — | — | — | 1 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Topotecan |
| INN | topotecan |
| Description | Topotecan is a pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks. It has a role as an EC 5.99.1.2 (DNA topoisomerase) inhibitor and an antineoplastic agent. |
| Classification | Small molecule |
| Drug class | antineoplastics (camptothecin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1 |
Identifiers
| PDB | — |
| CAS-ID | 123948-87-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL84 |
| ChEBI ID | 63632 |
| PubChem CID | 60700 |
| DrugBank | DB01030 |
| UNII ID | 7M7YKX2N15 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,666 documents
View more details
Safety
Black-box Warning
Black-box warning for: Hycamtin, Topotecan, Topotecan hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,678 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use